Olink publishes 2021 annual report
Olink Holding AB (Nasdaq: OLK) has made its 2021 Annual Report available on its website, showcasing its commitment to advancing proteomics. The company collaborates with biopharmaceutical firms and academic institutions to enhance understanding of human biology, aiming for impactful healthcare solutions. Established in 2016, Olink operates globally, focusing on pivotal scientific discoveries across various disease areas. The report reflects Olink's dedication to both innovation and patient outcomes.
- Accessible 2021 Annual Report highlighting ongoing efforts in proteomics.
- Global presence and collaborations with major biopharmaceutical companies.
- Focus on impactful science in improving patient healthcare.
- None.
UPPSALA, Sweden, March 17, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2021 is now available on the Company’s website at https://investors.olink.com/.
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
IR Contact
Jan Medina, CFA, VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com
Media Contact
Andrea Prander, Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com
